A booster dose of the COVID-19 vaccine developed by Pfizer Inc (PFE.N) and German partner BioNTech SE (22UAy.DE) restored efficacy to 95.6 per cent against the virus, including the Delta variant, data released by the companies from a large study showed on Thursday.
The companies said in a press release the trial, which has not been peer-reviewed, tested 10,000 participants aged 16 and older, and found that the booster shot had a favourable safety profile.
The trial results come a day after the U.S. Food and Drug Administration authorized booster doses of the COVID-19 vaccines from Moderna Inc (MRNA.O) and Johnson & Johnson (JNJ.N), and said Americans could choose a different shot from their original inoculation as a booster.
Source: Jordan News Agency